Australia - englanti - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 2000 iu/ml - injection, solution - excipient ingredients: glycine; sodium chloride; dibasic sodium phosphate dihydrate; water for injections; polysorbate 80; monobasic sodium phosphate - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs

Yhdysvallat - englanti - NLM (National Library of Medicine)

amgen inc - darbepoetin alfa (unii: 15uq94pt4p) (darbepoetin alfa - unii:15uq94pt4p) - darbepoetin alfa 10 ug in 0.4 ml - aranesp is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and patients not on dialysis. aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. aranesp has not been shown to improve quality of life, fatigue, or patient well-being. aranesp is not indicated for use: •       in patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. •       in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. •       in patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. •       as a substitute for rbc transfusions in patients who require immediate correction o

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 16.8 µg/ml (human recombinant erythropoietin (r-huepo cho));  ; epoetin alfa 16.8 µg/ml - solution for injection - 2000 iu/ml - active: epoetin alfa 16.8 µg/ml (human recombinant erythropoietin (r-huepo cho))   excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection active: epoetin alfa 16.8 µg/ml excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho));  ; epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho)); epoetin alfa 33.6 µg/ml - solution for injection - 4000 iu/ml - active: epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho))   excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection active: epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho)) excipient: albumin dibasic sodium phosphate dihydrate glycine metacresol monobasic sodium phosphate dihydrate water for injection active: epoetin alfa 33.6 µg/ml excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram - injection, solution - excipient ingredients: water for injections; polysorbate 80; dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate; sodium chloride; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate; sodium chloride; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy